Latest Breaking News On - Nexalin gen - Page 1 : comparemela.com

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA ... | Region

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device

FDA OKs Trials for Nexalin's Sleep and Anxiety Therapy Headset

The FDA has agreed on the design for Nexalin's planned clinical studies of the Gen-3 HALO Clarity, targeting insomnia and anxiety.

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

HOUSTON, TX, May 22, 2024 Nexalin Technology, Inc. is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury Registry Coalition ..

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, TEXAS, April 25, 2024 Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained.